RV
RVMD.US Revolution Medicines Inc
- Market cap
- USD 35.2B
- P/E
- -
- P/B
- 15.03x
- ROE
- -83.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is RVMD.US undervalued?
Graham numberThe Graham number of Revolution Medicines Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Revolution Medicines Inc fundamental analysis
No fundamental analysis for Revolution Medicines Inc yet.
Revolution Medicines Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Revolution Medicines Inc
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-a…
Full company profileRevolution Medicines Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Revolution Medicines Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 0.00 | 20.2M | 50.0M | 43.0M | 29.4M | 35.4M | 11.6M | 0.00 | 0.00 | 263M |
| Gross Profit | -26.6M | 20.2M | 50.0M | 43.0M | 29.4M | 35.4M | 11.6M | -592M | -16.6M | - |
| Operating Income | -31.1M | -40.3M | -54.1M | -111M | -188M | -258M | -487M | -690M | -1.18B | -1.76B |
| EBITDA | -29.8M | -39.9M | -48.6M | -102M | -180M | -239M | -430M | -589M | -1.09B | -1.90B |
| Net Income | -31.1M | -41.8M | -47.7M | -108M | -187M | -249M | -436M | -600M | -1.13B | -2.01B |
| EPS | -0.85 | -1.15 | -1.31 | -1.62 | -2.57 | -3.08 | -3.86 | -3.58 | -5.95 | -9.34 |
| Balance Sheet | ||||||||||
| Total Assets | 15.1M | 171M | 221M | 567M | 738M | 812M | 2.06B | 2.56B | 2.35B | 4.30B |
| Total Liabilities | 10.5M | 73.9M | 68.0M | 92.7M | 135M | 127M | 236M | 293M | 723M | 1.90B |
| Shareholders' Equity | 4.53M | 96.7M | 153M | 475M | 603M | 685M | 1.83B | 2.27B | 1.63B | 2.40B |
| Cash & Short-term Investments | 9.08M | 69.6M | 123M | 441M | 577M | 645M | 1.85B | 2.29B | 2.03B | 3.65B |
| Total Debt | - | 318K | 172K | 32.7M | 66.6M | 64.2M | 87.9M | 136M | 159M | 639M |
| Cash Flow | ||||||||||
| Operating Cash Flow | -25.1M | 1.21M | -49.6M | -100M | -147M | -224M | -351M | -557M | -898M | -1.54B |
| Capital Expenditure | 1.58M | 1.50M | 2.59M | 2.93M | 6.53M | 10.8M | 7.73M | 10.3M | 16.0M | 10.0M |
| Free Cash Flow | -26.7M | -286K | -52.2M | -103M | -154M | -235M | -358M | -568M | -914M | -1.55B |
| Ratios | ||||||||||
| ROE | -687.0% | -43.2% | -31.2% | -22.8% | -31.0% | -36.3% | -23.9% | -26.5% | -69.3% | -83.6% |
| ROA | -206.5% | -24.5% | -21.6% | -19.1% | -25.4% | -30.6% | -21.2% | -23.5% | -48.0% | -46.6% |
| Net Profit Margin | - | -207.2% | -95.2% | -251.6% | -636.6% | -703.0% | -3,768.3% | - | - | -762.1% |
| Debt to Equity | - | 0.00x | 0.00x | 0.07x | 0.11x | 0.09x | 0.05x | 0.06x | 0.10x | 0.27x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Revolution Medicines Inc dividends
Revolution Medicines Inc has not paid dividends in the last 9 fiscal years.
Who owns Revolution Medicines Inc
- Insiders 1.83%
- Institutions 98.11%
- Public & others 0.06%
- Shares outstanding 216M
- Free float 187M
Top funds holding RVMD.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 6.47M | 2.99% | +0.80% | Sep 2026 |
| Vanguard Small Cap Index | 4.58M | 2.12% | -1.38% | Sep 2026 |
| American Funds Growth Fd of Amer A | 2.96M | 1.37% | 0.00% | Sep 2026 |
| Vanguard MStar Small Cap Growth Indx Inv | 2.55M | 1.18% | -4.38% | Sep 2026 |
| Fidelity Growth Company Fund | 2.47M | 1.14% | 0.00% | Aug 2026 |
| JPMorgan Large Cap Growth I | 2.39M | 1.11% | +11.70% | Sep 2026 |
| Vanguard Health Care Inv | 1.99M | 0.92% | -5.03% | Sep 2026 |
| MFS Mid Cap Growth A | 1.56M | 0.72% | 0.00% | Sep 2026 |
| iShares Biotechnology ETF | 1.50M | 0.69% | -0.32% | Oct 2026 |
| iShares Russell Mid-Cap Growth ETF | 1.08M | 0.50% | -0.07% | Oct 2026 |
| Fidelity OTC | 1.00M | 0.46% | 0.00% | Aug 2026 |
| Franklin DynaTech Fund A | 1.00M | 0.46% | 0.00% | Sep 2026 |
| Janus Henderson Enterprise D | 978K | 0.45% | 0.00% | Sep 2026 |
| Janus Henderson Forty S | 938K | 0.43% | 0.00% | Sep 2026 |
| Fidelity Extended Market Index | 931K | 0.43% | -4.30% | Sep 2026 |
| iShares Russell Mid-Cap ETF | 813K | 0.38% | -0.06% | Oct 2026 |
| State Street® SPDR® S&P® Biotech ETF | 763K | 0.35% | +2.68% | Oct 2026 |
| Fidelity Select Biotechnology | 735K | 0.34% | +2.83% | Aug 2026 |
| Fidelity Mid Cap Index | 723K | 0.33% | -0.64% | Sep 2026 |
| iShares Russell 1000 Growth ETF | 721K | 0.33% | +0.09% | Oct 2026 |
Top institutions holding RVMD.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 13.7M | 6.33% | +22.15% | Jun 2026 |
| Farallon Capital Management, L.L.C. | 13.6M | 6.27% | -0.40% | Jun 2026 |
| FMR Inc | 12.2M | 5.64% | +44.14% | Jun 2026 |
| Baker Bros Advisors LP | 11.4M | 5.29% | +19.76% | Jun 2026 |
| Jupiter Topco LLC | 10.7M | 4.96% | 0.00% | Jun 2026 |
| Darwin Global Management, Ltd. | 10.6M | 4.91% | +380.77% | Jun 2026 |
| Vanguard Capital Management, LLC | 9.09M | 4.20% | +8.69% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 8.29M | 3.84% | +10.56% | Jun 2026 |
| Nextech Invest, Ltd. | 7.60M | 3.51% | 0.00% | Jun 2026 |
| Paradigm Biocapital Advisors LP | 6.36M | 2.94% | -4.42% | Jun 2026 |
| UBS Group AG | 5.45M | 2.52% | +24.20% | Jun 2026 |
| State Street Corp | 4.90M | 2.26% | +11.23% | Jun 2026 |
| Capital World Investors | 4.01M | 1.85% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 3.94M | 1.82% | +18.11% | Jun 2026 |
| Wellington Management Company LLP | 3.84M | 1.78% | -36.24% | Jun 2026 |
| JPMorgan Chase & Co | 3.30M | 1.52% | +994.27% | Jun 2026 |
| Bvf Inc | 2.97M | 1.37% | +3.79% | Jun 2026 |
| Alphabet Inc | 2.95M | 1.36% | -10.51% | Jun 2026 |
| Casdin Capital, LLC | 2.58M | 1.19% | 0.00% | Jun 2026 |
| Deerfield Management Co | 2.39M | 1.11% | +4.14% | Jun 2026 |
Revolution Medicines Inc company profile
- Company name
- Revolution Medicines Inc
- Ticker
- RVMD.US
- Exchange
- USA Stocks
- Listed since
- Feb 13, 2020
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 883
- Fiscal year end
- December
- Address
- 700 Saginaw Drive, Redwood City, CA, United States, 94063
- Phone
- 650 481 6801
- Website
- revmed.com
About Revolution Medicines Inc
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial; and RMC-8839 (G13C). Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Revolution Medicines Inc management
10- Dr. Mark A. Goldsmith M.D., Ph.D.CEO, President & Chairman · born 1962
- Mr. Jack AndersChief Financial Officer · born 1977
- Ms. Margaret A. Horn J.D.Chief Operating Officer · born 1963
- Mr. Jeffrey Cislini J.D.Senior VP, General Counsel & Corporate Secretary · born 1975
- Dr. Stephen M. Kelsey FRC Path., FRCP, M.D.Senior Advisor · born 1961
- Dr. Martin D. Burke M.D., Ph.D.Co-Founder & Chairman of Scientific Advisory Board
- Dr. Michael A. Fischbach Ph.D.Academic Co-Founder & Member of Scientific Advisory Board · born 1981
- Dr. Kevan M. Shokat Ph.D.Academic Co-Founder & Member of Scientific Advisory Board
- Mr. Walter Reiher Ph.D.Chief Information Officer
- Ms. Jan Smith Ph.D.Chief Scientific Officer